“Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?” by Kleber Yotsumoto Fertrin, provides a comprehensive overview of how to identify and treat iron deficiency (ID) in patients who also have chronic inflammatory conditions.
Key aspects covered in the document include:
- The Diagnostic Challenge: Chronic inflammatory conditions—such as chronic kidney disease (CKD), heart failure (HF), liver disease, and rheumatologic disorders—can make it difficult to interpret standard laboratory markers like ferritin. Inflammation often causes an acute-phase reaction, which can elevate ferritin levels, potentially masking absolute iron deficiency.
- Interpreting Iron Status:
- Ferritin: While ferritin is the recommended marker for investigating ID, its reliability is diminished by inflammation. The document suggests that while the WHO threshold for absolute ID is <15 µg/L, a threshold of 30 µg/L is often used for higher sensitivity; however, in patients with CICs, these markers require careful clinical interpretation, often needing values higher than 30 µg/L to identify deficiency.
- Transferrin Saturation (TSAT): TSAT is presented as a helpful tool in CICs. Generally, a TSAT <20% is often used to diagnose ID in the presence of inflammation.
- Management Strategies:
- Investigation: Clinicians should always investigate the underlying causes of iron deficiency, such as occult blood loss (e.g., GI or uterine) or impaired absorption.
- Treatment Options: Treatment decisions involve choosing between oral and parenteral (intravenous) iron. While oral iron is cost-effective and should be considered, parenteral iron is frequently superior for patients with conditions like IBD, HF, or CKD, or those who cannot tolerate oral iron.
- Risks: Parenteral iron carries potential risks, including allergic reactions (though rare with modern formulations) and hypophosphatemia, particularly with certain formulations like ferric carboxymaltose (FCM) and ferric derisomaltose. Iatrogenic iron overload is also a concern, especially in patients with CKD, necessitating careful monitoring.
- Clinical Guidance: The document includes a clinical case study and tables summarizing common oral iron supplements and IV iron preparations, including their characteristics, potential side effects, and average wholesale pricing. It emphasizes a “pragmatic way” of interpreting diagnostic tests to make personalized treatment decisions for patients with multiple comDiagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?orbidities.The provided document, titled “Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?” by Kleber Yotsumoto Fertrin, provides a comprehensive overview of how to identify and treat iron deficiency (ID) in patients who also have chronic inflammatory conditions.
Key aspects covered in the document include:
- The Diagnostic Challenge: Chronic inflammatory conditions—such as chronic kidney disease (CKD), heart failure (HF), liver disease, and rheumatologic disorders—can make it difficult to interpret standard laboratory markers like ferritin. Inflammation often causes an acute-phase reaction, which can elevate ferritin levels, potentially masking absolute iron deficiency.
- Interpreting Iron Status:
- Ferritin: While ferritin is the recommended marker for investigating ID, its reliability is diminished by inflammation. The document suggests that while the WHO threshold for absolute ID is <15 µg/L, a threshold of 30 µg/L is often used for higher sensitivity; however, in patients with CICs, these markers require careful clinical interpretation, often needing values higher than 30 µg/L to identify deficiency.
- Transferrin Saturation (TSAT): TSAT is presented as a helpful tool in CICs. Generally, a TSAT <20% is often used to diagnose ID in the presence of inflammation.
- Management Strategies:
- Investigation: Clinicians should always investigate the underlying causes of iron deficiency, such as occult blood loss (e.g., GI or uterine) or impaired absorption.
- Treatment Options: Treatment decisions involve choosing between oral and parenteral (intravenous) iron. While oral iron is cost-effective and should be considered, parenteral iron is frequently superior for patients with conditions like IBD, HF, or CKD, or those who cannot tolerate oral iron.
- Risks: Parenteral iron carries potential risks, including allergic reactions (though rare with modern formulations) and hypophosphatemia, particularly with certain formulations like ferric carboxymaltose (FCM) and ferric derisomaltose. Iatrogenic iron overload is also a concern, especially in patients with CKD, necessitating careful monitoring.
- Clinical Guidance: The document includes a clinical case study and tables summarizing common oral iron supplements and IV iron preparations, including their characteristics, potential side effects, and average wholesale pricing. It emphasizes a “pragmatic way” of interpreting diagnostic tests to make personalized treatment decisions for patients with multiple comorbidities.Why do at least half of people with PA have iron deficiency with or without anemia?
Iron deficiency tracks with PA because both point back to the same damaged tissue. Parietal cells make two things: intrinsic factor and hydrochloric acid. Autoimmune destruction takes out both functions together, not just whichever one is getting attention.The acid connection matters specifically for iron. Dietary iron is mostly ferric (Fe3+), and it needs an acidic environment to get reduced to ferrous (Fe2+) before DMT1 transporters in the duodenum can absorb it. Achlorhydria removes that step. So even with adequate dietary iron, absorption drops.A few other mechanisms stack on top of that:**H. pylori overlap.** A lot of autoimmune gastritis has current or past H. pylori involvement, and H. pylori causes iron deficiency through its own pathway (hepcidin dysregulation, direct mucosal effects) independent of the acid issue. Where that overlap exists, you get two iron-suppressing mechanisms running at once.
**Sequencing.** Iron deficiency tends to show up years before B12 deficiency becomes clinically apparent (Hershko 2006, already in your framework). The gastritis process is progressive — acid output drops before parietal cell mass is destroyed enough to also tank intrinsic factor and B12 absorption. Iron stores are smaller and turn over faster than B12 stores, so they deplete first even though the underlying lesion is the same one that will eventually cause the B12 problem.
**General mucosal damage.** Atrophic gastritis reduces absorptive surface area and function broadly, not just for the two nutrients most discussed.
Other deficiencies that cluster for the same structural reasons:
– **Calcium** — calcium carbonate absorption is acid-dependent; achlorhydria impairs it the same way it impairs iron
– **Zinc and magnesium** — both have some acid-dependent absorption components
– **Vitamin C** — gastric juice normally concentrates ascorbic acid; atrophic gastritis lowers intragastric vitamin C levels
– **Folate** — not primarily acid-dependent, but frequently deficient alongside B12 in the same patients, which is part of why your framework treats deficiencies as needing simultaneous correction rather than sequential
– **Fat-soluble vitamins (A, D, E, K)** — relevant mainly where celiac disease clusters in, since that’s a separate malabsorptive process layered on topThere is also a polyautoimmunity angle here too: PA patients have elevated rates of Hashimoto’s, celiac, T1D, and vitiligo. Celiac specifically adds its own malabsorption on top of the gastric mechanism, so in patients with both conditions the deficiency picture gets broader than what gastritis alone explains.
Iron deficiency in PA is a predictable output of the same mechanism failure, just hitting a nutrient with faster depletion kinetics. It is also challenging to diagnose especially in people with autoimmune disorders because inflammation falsely raises ferritin.
References:
**Why iron deficiency shows up before B12 deficiency**
Autoimmune gastritis destroys acid production before it destroys enough parietal cell mass to also take out intrinsic factor and B12 absorption. Iron deficiency surfaces years to decades earlier because of that sequencing, not because it’s a separate process.
Autoimmune gastritis impairs both iron and vitamin B12 uptake, but iron deficiency shows up at a younger age, often many years before pernicious anemia develops. [NCBI](https://www.ncbi.nlm.nih.gov/books/NBK540989/)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065578/
Iron deficiency is a known complication of achlorhydria and can precede the onset of pernicious anemia. [Springer](https://link.springer.com/article/10.1007/s12026-016-8841-7)
https://pubmed.ncbi.nlm.nih.gov/16239424/
**Why achlorhydria blocks iron absorption specifically**
Reduced gastric acid impairs the conversion of dietary iron into an absorbable form, and lower ascorbic acid levels compound the problem, together driving the iron deficiency seen in autoimmune gastritis. [NCBI](https://www.ncbi.nlm.nih.gov/books/NBK540989/)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065578/
**Why H. pylori adds a second, independent pathway to iron deficiency**
H. pylori can suppress iron absorption through hepcidin, the hormone that governs how much iron the gut releases into circulation, entirely apart from any effect on stomach acid.
Hepcidin has been reported to rise in patients infected with H. pylori, acting as an acute-phase reactant to the gastric inflammation the infection produces. [nih](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261815/)
https://www.intechopen.com/chapters/49909
**Why ferritin alone can mislead in inflammatory conditions**
Ferritin rises with inflammation independent of actual iron stores, which is why transferrin saturation has to be read alongside it rather than ferritin used on its own.
Diagnosis and management of iron deficiency in chronic inflammatory conditions
https://ashpublications.org/hematology/article/2020/1/478/474369/Diagnosis-and-management-of-iron-deficiency-in
**Why PA rarely travels alone**
Autoimmune atrophic gastritis is frequently found alongside thyroid disease, including Hashimoto’s thyroiditis, and type 1 diabetes, with other associations including Addison’s disease, vitiligo, and related autoimmune conditions. [nih](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734642/) The elevated rate of clustering is reason enough to check for other autoimmune conditions once one has been diagnosed. [nih](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734642/)
https://pubmed.ncbi.nlm.nih.gov/30561426/